Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 3Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

HER2-positive Breast Cancer 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 69Letrozole 62Cyclophosphamide 61Paclitaxel 60pertuzumab 52Specimen Handling 52Docetaxel 50abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 33Blood Specimen Collection 33Tamoxifen 32sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Taxoids × Breast × Clear all
NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡